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Orally sustained and controlled drug delivery systems are usu-
ally used to improve release behavior of drugs to meet different
conditions in the body, which includes single unit dosage forms
(SUF) and multiple unit dosage forms (MUFs) (Abdul et al.,
2010). The latter consists of pellets, granules, microparticles
and minitablets. Compared with SUF, MUFs present several
advantages (Liu et al., 2012): (i) The multiparticulates spread
uniformly throughout the gastrointestinal tract (GIT), which
can reduce local irritation of active ingredient, enhance drug
absorption and lower the ﬂuctuation of peak plasma. (ii)
MUFs possess constant transit time in the GIT, which can
avoid dose bumping and improve safety. (iii) The defect of
individual unit has no serious effect on efﬁcacy. (iv) Inter-
and intra-individual variations in the bioavailability caused
for instance by food effects can also be reduced.
Pellets are a class of globular entity consisting drugs and
excipients, which normally are no more than 2.5 mm in diam-
eter. Coated pellets have effects of sustained release and mask-
ing taste. Tablets consisting coated pellets can contain
incompatible drugs or drugs with different release rates.
In contrast with pellet-containing capsules, tablets are more
tamper resistant, easier to swallow and of lower cost in indus-
trial production. With the application of coated pellets-con-
taining tablets, tablets will be completely disintegrated into
pellets and drug can be subsequently released from the pellets
(Table 1). In fact, the MUF should not fuse into the non-dis-
integrating matrix during compaction and then disintegrate
rapidly into the individual pellets in GIT. Compaction process
has no effect on the release characteristics.
Compared with the preparation of common tablets, the
technologies of pellet-containing tablets are more complex.
At present, available tablets in the market mainly include pro-
ton pump inhibitors and some drug with narrow therapeutic
window (Table 1). The key point in the preparation of coated
pellet-containing tablet is to ensure the integrity of the coatingTable 1 Overview of marketed tablets containing coated pellets.
Trade name API Therapeutic role Formula
Betaloc ZOK Metroprolol succinate Hypertension Multi-un
Harnal D Tamsulosin Hydrochloride Hyperplasia
of prostate
Multi-un
Losec MUPS Omeprazole Magnesium Peptic ulcer Multi-un
Nexium Esomeprazole magnesium Peptic ulcer Multi-un
Prevacid Lansoprazole Peptic ulcer Multi-unﬁlm, which must be able to withstand the compression force.
Many studies (Altaf et al., 1998; Miller et al., 1999) showed
that coating ﬁlms usually suffer from damages in the compres-
sion process, which will inﬂuence drug release behavior. Cur-
rent researches mainly focus on the optimization for type
and diameter of pellet cores, type and dosage of coating poly-
mers and plasticizer, buffer excipients, as well as technological
parameters (Fig. 1). All of these will be discussed speciﬁcally in
this review and put forward corresponding solutions.2. Formulation factor
2.1. Pellet core
Core features of coated pellets are essential to the tabletting of
coated pellets. Cores, with good elasticity and toughness,
ought to meet the requirements of deformation during tablet-
ting, which can reduce undesirable effects following elastic
recovery on coating ﬁlms and ensure intact coating ﬁlms.
Determinant factors of tensile strength contain core composi-
tion, size, porosity, and so on. Coated cores with good tensile
strength can withstand pressure in the tabletting process and
maintain intact coating ﬁlm.
2.1.1. Core composition
Pellets itself must have certain tensile strength, and thus main-
tain release behavior of pellets following tabletting. The ﬁrst
issue to be considered is the composition of pellets. Compo-
nents of pellets include diluents and adhesive, such as lactose,
starch, microcrystalline cellulose (MCC), hydroxymethyl cellu-
lose, polyvinyl alcohol, Polyvinylpyrrolidone (PVP), and
hydroxypropyl methyl cellulose (HPMC).
Due to the good rheological properties that enhance the
plasticity of other excipients and produce bonding effects,
MCC is called balling promoter and applied widely. The mech-
anism of tabletting with MCC-containing pellets was studiedtion Manufacturer
ites sustained pellet-containing tablet AZN
ites sustained pellet-containing disintegrating tablet Astellas
ites enteric pellet-containing tablet AZN
ites enteric pellet-containing tablet AZN
ites enteric pellet-containing disintegrating tablet Takeda
Figure 1 Inﬂuence factors on quality of pellet-containing tablets.
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sented permanent deformation not fragmentation in the tablet-
ting process. The increase in deformation degree of pellets
would decrease distance between pellets, which ultimately
strengthened binding force among pellets and increased hard-
ness of tablets in the meantime. For the core materials with
good rheological properties, the tabletting force can be
increase appropriately. In addition, some excipients can fur-
ther improve compressibility of MCC-containing pellets. Pel-
lets formed from MCC with other excipients were more
resistant to compression than those formed from MCC alone,
such as lactose/MCC, dibasic calcium phosphate/MCC. A soft
material (polyethylene glycol) can also be used to modulate
compression behavior and compressibility of the pellets
(Nicklasson and Alderborn, 1999). This change possibly is
due to the pellets composed of blended excipients behaved
differently during deformation.
However, for insoluble drugs, drugs of chemical incompat-
ibility with MCC, and some other easily adsorbed on MCC
ﬁbers, MCC will probably retard drug release to some extent.
At this time, MCC is inappropriate to be used to make pellet
cores. Bornho¨ft et al. (2005) found that r-carrageenan was a
very promising substitute for MCC in pelletization. Compared
with MCC pellets, the preparation of r-carrageenan pellets
needed more water, and presented more robust with respect
to ﬂuctuations in water content. Meantime, systematic investi-
gations were conducted to evaluate effects of other ingredients.
Four drugs (acetaminophen, mesalamine, theophylline and
hydrochlorothiazide) and four ﬁllers (lactose, mannitol, maize
starch and dicalciumphosphate dihydrate) were selected in the
experiment (Thommes and Kleinebudde, 2006, 2006). The
result showed that all pellets have good shape and size, which
indicated that r-carrageenan was a suitable pelletization.
Poorly soluble drugs loaded in r-carrageenan pellets by wet
extrusion–spheronization presented better release behavior
than MCC pellets. This was attributed to the time poorlysoluble drugs releasing from MCC pellets exceeding the gas-
tro-intestinal passage time. Ghanam and Kleinebudde
(2011)) developed bisacodyl sustained pellet-containing tab-
lets. Pellets were prepared by bisacodyl and r-carrageenan or
MCC, and coated with a mixture of Kollicoat MAE 30 DP
and Eudragit NE 30 D. In vitro dissolution test showed that
r-carrageenan pellet tablets released over 80%, but MCC
pellet tablets were only about 20–24%.2.1.2. Porosity
The pellet porosity determined the degree of their deformation,
and would subsequently inﬂuence compression of pellets and
release behavior of drugs. Johansson and Alderborn (1996)
investigated the degree of deformation and densiﬁcation of
MCC-containing pellets. The results showed that the low
porosity pellets presented only limited local permanent defor-
mation and no changes in porosity during compression, but
high porosity pellets with the same particle size appeared a
big change in shape and porosity. Tuno´n et al. (2003) investi-
gated the deformation degree and release behavior of various
reservoir pellets with different porosity after compression,
and found that the deformation degree of pellets followed tab-
letting was directly related to the change of amount of drug
release. Pellets with high porosity appeared high degree of
deformation and densiﬁcation, but release behavior of drug
was hardly inﬂuenced, which indicated no destruction on coat-
ing ﬁlm of pellets. Scanning electron microscopy also pre-
sented that coating ﬁlm did not tend to become convoluted
and still cover ﬁrmly on the pellet surfaces. This could be
attributed to the increase of cushion space of coating ﬁlm when
pellets with high porosity were compressed, which reduced
destructive effects from compaction and change of permeabil-
ity of pellets. In contrast, the cushion space of pellets with
low porosity diminished and the large proportion of pellets
was in contact with the punches and die during compaction.
510 X. Tan, J. HuConsequently, the risks of damage on coating ﬁlms were
enhanced. Compaction of pellets with high porosity would
considerably affect the degree of densiﬁcation and deforma-
tion, but slightly effect on drug release. For low porosity pel-
lets, the inﬂuence of compaction was obvious, whereas
degree of densiﬁcation and deformation was slight. Accord-
ingly, pellets with high porosity are more suitable to be made
into tablets to maintain release behavior. After regulating
porosity of pellet cores, compaction technologies can be opti-
mized to achieve ideal drug release.
2.1.3. Particle size
Different diameters of pellet cores will directly inﬂuence com-
pressibility of tabletting excipients, and subsequently have
effects on compression performance of pellets and drug release.
Johansson et al. (1998) developed two MCC-containing pellets
with different diameter (i.e. 425–500 lm and 1250–1400 lm) by
extrusion–spheronization. Meantime, the inﬂuences of tablet-
ting of coated pellets dominating mechanisms of compression
were investigated. The porosity and tensile strength of tablets
were determined, and the results showed that mechanisms of
compression for the pellets were deformation and densiﬁcation.
The original size of pellets did not affect porosity changes of
tablets, but the degree of deformation of individual pellets
was related with core sizes, i.e. degree of deformation enhanced
with increasing size. Dashevsky et al. (2004) found that smaller
pellets, at the same weight, presented the higher surface area,
and thus had a thinner coating and tended to the rupture of
coating ﬁlms. The release rate of drugs from coated pellets slo-
wed down with the increase of core size and coating level. The
propranolol HCl release from Kollicoat SR 30 D coated pel-
lets decreased with increasing pellets size.
2.1.4. Core drying
Drying methods on pellet cores can affect porosity of pellets
and subsequently inﬂuence compression performance of pel-
lets. Four different techniques (Bashaiwoldu et al., 2004),
including freeze-drying, ﬂuid-bed drying, hot air oven drying
and desiccation with silica-gel, were compared and summa-
rized. According to the different rate of moisture removal,
heating method and mass transfer, the different drying tech-
niques give rise to pellets of different structural and mechanical
properties. The results showed that deformability was depen-
dent with drying techniques, and could be sorted from low
to high, i.e. freeze-drying, ﬂuid-bed drying, hot air oven drying
and desiccation with silica-gel. The deformability of pellets was
positively related with porosity, and pellets tended to deform
with increasing porosity. Moreover, drying rate had effect on
the deformability and compressibility of pellets, and deforma-
bility of pellets increased along with the enhancement of drying
rate.
2.2. Coating
Polymeric coatings are applied to meet various purposes in
pharmaceutical ﬁeld. They can control drug release from oral
dosage forms, improve the chemical stability of drugs by set-
ting up a physical barrier to the inﬂuence of external environ-
mental, and mask repulsive taste and odor (Ensslin et al., 2009;
Goole et al., 2008; Ye et al., 2007). Several problems related
with polymeric materials (Technological factors will beexplained blow) maybe occur in the coating process. With
increasing temperature, mobility of polymer chains increases,
boundary between polymer particles eliminates, polymer parti-
cles bond mutually, and coating membranes take shape ulti-
mately after mechanical deformation. But in the meantime,
incomplete fusion between colloidal particles perhaps happens
in the coating process. Shrinkage of ﬁlm usually produces
residual cohesion during solvent evaporation. Thermal expan-
sion properties between coating ﬁlm and substrate exist differ-
ences. All these elements can contribute to the cracks or defects
of coating ﬁlms. Moreover, shape and density of coated pellets
change sharply during tabletting, as well as friction and colli-
sion between pellets and die possibly damage polymeric ﬁlm.
These two crucial reasons will deprive pellets of controlled
release performance. In consequence, before compression of
coated pellets, different mechanical properties that coating
ﬁlms presented during receiving different types of stress should
be investigated completely.2.2.1. Coating polymer
Polymers currently used in the coating fall into two broad
groups: cellulosic and acrylic polymers. Cellulosic polymer,
such as ethylcellulose, is used for extended-release. The acrylic
polymers are marketed under the trade names of Eudragit or
Kollicoat, which mainly are used to control drug release and
mask taste. These two polymers can be formulated as aqueous
colloidal dispersions and organic solutions.
Due to the low puncture strength and elongation (<5%)
and weak mechanical properties, EC used for coating ﬁlm
tends to be damaged and then loses the function of sus-
tained-release (Bodmeier and Paeratakul, 1994). Mechanical
properties of EC were hardly strengthened by adding plasti-
cizer, nor curing of the pseudo-latex-cast ethylcellulose ﬁlms
worked. Hosseini et al. (2013) tried to layer tabletting excipi-
ents (e.g., MCC, lactose or sorbitol) onto the ethylcellulose-
coated pellets to form a cushion layer to protect the integrity
of the brittle ethyl cellulose coating during compression. How-
ever, the result showed that tabletting excipients are still insuf-
ﬁcient to maintain the integrity of coating ﬁlm. Only
incorporating glidant (e.g., magnesium stearate or aerosil) into
the cushion layer or between the cushion layer and the ethyl
cellulose coating, the compression effect on drug release can
be reduced. Nevertheless, craft process became complex. Elon-
gation of EC ﬁlm can be improved by combining EC aqueous
dispersion with Acryl-EZE. Acryl-EZE is a fully formu-
lated, dry enteric acrylic coating system dispersible in water,
for the application of an enteric ﬁlm coating to multi-particu-
late solid dosage forms. Li et al. (2012) prepared aspirin pellets
coated with Surelease (aqueous ethylcellulose dispersion)
and Acryl-EZE. In vitro tests showed 30% aspirin released
from tablets at the ﬁrst two hours, and the rest released in
the later 10 h. Weibull curve ﬁtting equations indicated that
drug release from pellet-containing tablets met ﬁrst-order rate
process.
Compared with EC ﬁlms, acrylic polymers are more suit-
able for coating of pellets intended to be compressed into tab-
lets (Bodmeier and Paeratakul, 1994). Eudragit NE 30 D is
the aqueous dispersion of a neutral copolymer based on ethyl
acrylate and methyl methacrylate. This dispersion was highly
ﬂexible and suitable for matrix structure. Due to the high elon-
gation at break of approximately 600%, Eudragit NE30D
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ﬂexible enough to withstand deformation forces during tablet-
ting. Eudragit RS and Eudragit RL 30D showed insufﬁ-
cient elongation, but they also can be used for tabletting
after adding plasticizers. Abbaspour et al. (2008) developed
ibuprofen disintegrating sustained-release tablets comprising
coated pellets. Tablets were designed to disintegrate into sus-
tained-release pellets after oral ingestion. In order to maintain
the integrity of the pellet ﬁlms, coated membrane materials
contained Eudragit RS 30D and RL 30D in 4:1 ratio and dif-
ferent levels of triethyl citrate. Mechanical tests showed that
the coated pellets had no signiﬁcant effect on yield point and
elastic modulus of the pellets. Scanning electron microscope
graphs and in vitro dissolution test showed no apparent dam-
age to the coated pellets after compaction process.
Eudragit L 30D55 is the aqueous dispersion of anionic
polymers with methacrylic acid as a functional group and a
milky white liquid of low viscosity. Due to the strong inter-
chain hydrogen bonding caused by the impacts of carboxyl
groups, Eudragit L 30D55 resulted in weak and brittle ﬁlms.
Pellets coated with Eudragit L 30D55 alone are easy to
appear with cracks in the range of 5–50 lm after compression,
and cannot meet the requirements of enteric formulations and
sustained-release. Eudragit L 30D55 can be blended with
Eudragit NE 30D with good ﬂexibility, and this mixed coat-
ing ﬁlms at a certain proportion can maintain the integrity of
pellets. When the ratio of EudragitNE 30D in blends is more
than 10%, ﬁlm strength of pellets can be enhanced signiﬁcantly
and more suitable for tabletting, but too much dosage will
retard drug release in the intestinal tract. EI-Malah and
Nazzal (2008) tried to evaluate the mechanical and thermal
properties of ﬁlms prepared from Eudragit NE 30D and L
30D-55 blends. With the increase of Eudragit NE 30D con-
centrations, miscibility, softness, and decreased stiffness of the
ﬁlms enhanced correspondingly. Cast ﬁlms were evaluated by
texture analysis and differential scanning calorimetry. The
mixture proportions of Eudragit NE 30D and L 30D-55
respectively are 50:50, 67:33, 75:25 and 80:20, which were eval-
uated by texture analysis and differential scanning calorimetry.
The data obtained showed that polymeric blends can be per-
mitted as coating materials. When the concentration of Eudra-
git NE 30D is at least 80%, miscible and homogenous blends
could be obtained, which inﬂuenced drug release. The lag time
and drug release rate were controlled by the theoretical weight
gain of the beads and the concentration of EudragitNE 30D.
The blend at 80:20 ratio retarded drug release by approxi-
mately 7 h, but the blend at 80:20 ratio just only delayed drug
release by only 3.5 h. This was attributed to the homogeneous
mixture of the two polymers. Apart from screening coating
materials and adding plasticizers, additive protection can be
employed to withstand the compression force during tablet-
ting. Mesalamine sustained-release pellets coated with Eudra-
git S100 were compressed into tablets and then coated with
additional polymeric ﬁlms (Eudragit L 100-55) for colon-spe-
ciﬁc drug delivery (Bendas et al., 2010).
Kollicoat belongs to Polyvinylacetate copolymer colloidal
substances developed by BASF. Glass transition temperature
of Kollicoat is only in the range of 5–18 C. Due to the cer-
tain viscosity, antiadhesion agents will be added during coating
or storing. Dashevsky et al. (2004) compared three types of
membrane materials, Kollicoat SR 30 D, Aquacoat ECD
30 and blends of Kollicoat MAE 30 DP and KollicoatEMM 30 D. The results showed that the blends of Kollicoat
MAE 30 DP and EMM 30 D maintain sufﬁcient enteric prop-
erties of pellets. Kollicoat SR 30 D combined with 10% w/w
triethyl citrate could be used as ﬁlm material. While pellets
coated with Aquacoat ECD 30 were easy to rupture during
compression.
2.2.2. Plasticizer
Plasticizers work by embedding themselves between the chains
of polymers, spacing them apart and thus signiﬁcantly lower-
ing the glass transition temperature for the plastic. Concentra-
tion of plasticizer in the coating solution depends on several
factors, including polymeric properties, usage, and other
additives.
Given special requirements for the coating ﬁlms of pellets
during compression, types and amount of plasticizer must be
investigated in-depthly. The frequently used plasticizers
include triethyl citrate (TEC), dibutyl sebacate (DBS), propyl-
ene glycol (PPG), polyethylene glycol (PEG). Sawicki and
Lunio (2005) designed verapamil hydrochloride ﬂoating pellets
coated with Kollicoat SR30D. Three plasticizers were exam-
ined PPG, TEC and DBS (all at concentration of 10%). Due to
the solubility of TEC and DBS being less than PPG, drug
release was retarded and in vitro release presented signiﬁcant
differences. This was attributed to the different properties of
drugs, hydrophilic or hydrophobic plasticizers present variant
effects. Optimal plasticizers should present compatibility with
polymers, solubilize polymers and reduce Tg of polymers to
the greatest extent.
In addition, moisture is also essential for the successful com-
pression of coated pellets. Rujivipat and Bodmeier (2012)
investigated how important moisture play role in the coating
ﬁlms properties. Coated pellets were stored at different humid-
ity at room temperature for 1 month, including 52%, 75%,
84%, 95% and 100%RH. Tg of coating ﬁlm ultimately lowered
and reduced degree enhanced with increasing relative humidity.
To these brittle Eudragit L100-55 in the dry state, enhance-
ment of moisture can improve compressibility of pellets coated
with Eudragit L100-55 and avoid occurrence of crack.
2.2.3. Coating ﬁlm thickness
Coating weight affects ﬁlm thickness directly, and subse-
quently inﬂuences drug release. Coated pellets with thick ﬁlms
have strong toughness, but drug release from pellets probably
be delayed. Under the circumstances, pore-foaming agent
should be considered to be added (Table 2). Several tests indi-
cated that suitable coating weights can meet different require-
ments of drug release on the condition of no destruction on
coating ﬁlms. If isolation layers are employed, thickness of iso-
lation layer is determined according to the protection ability of
isolation layers and drug release behavior.
2.3. Tabletting excipient
The selection of optimal excipients is essential to tabletting of
pellets. There are several roles in the tabletting process: (i) It
can be used to ﬁll the space between pellets and reduce pressure
from compression. (ii) It can prevent direct contact between
pellets and mutual integration of polymeric ﬁlms, which con-
tribute to maintain integrity of coating ﬁlm. (iii) It can be uti-
lized to improve compressibility. (iv) Excipients with suitable
Table 2 Pore-foaming agents.
Hydrophilic liquid Glycerinum
PEG 200
Electrolyte NaCl
KCl
Na2SO4
Saccharides Lactose
Fructose
Saccharose
Mannose
Surfactant Polysorbate 80
Lauryl sodium sulfate
Polymer PEG
PVA
Hydrogels HPMC
CMC
Tragacanth
Foaming agent Carbonate
Bicarbonate
512 X. Tan, J. Husize can reduce occurrence of separated pellets and excipients,
improve uniformity of drug and decrease the difference of tab-
lets weight. Excipients are usually added to mixtures in the
form in the form of powder or granule (Altaf et al., 1999).
Habib et al. (2002) prepared placebo beads being the same size
with pellets by extrusion–spheronization followed by freeze
drying to avoid segregation occurrence leading to weight vari-
ation and content uniformity problems. Several factors decide
whether ﬁllers can be used as tabletting excipient, including
type, dosage, and physical and mechanical properties, such as
elasticity, plasticity, and porosity. Torrado and Augsburger
(1994) investigated the possible protective effect of different
excipients on the tabletting of granules coated with Eudragit
RS. The results showed that the order of least damage to the
coating was: polyethylene glycol 3350 < microcrystalline cellu-
lose < crospovidone < lactose < dicalcium phosphate. After
compared with each other, suitable excipient mixture was:
microcrystalline cellulose 50%, crospovidone 25% and poly-Table 3 Commercially available co-processed excipient.
Type Brand name Ingredie
Starch-based Advantose FS Fructose
StarCap 1500 Corn sta
Cellulose based Avicel HFE MCC-M
Avicel RC-591 MCC-N
Avicel RC-581 MCC-N
Avicel CL-611 MCC-N
Barcroft CS90 Calcium
ForMaxx Calcium
ProSolv SMCC50 MCC-Co
Xylitab200 Xylitol-N
Lactose-based Cellactose a-Lactos
Microcellac a-Lactos
StarLac100 a-Lactos
Sugar-based Di-Pac Sucrose-
CompressolS Mannito
LudiFlash Mannitoethylene glycol 3350 25%. Under this mixture ratio, damage
of the coating membranes was at very low compressional
pressure and minimum damage.
Excipient properties, such as size, bulk density, surface
morphology, and internal interaction, usually will inﬂuence
mobility, segregation occurrence, tablet hardness and drug
release behavior. With increasing demands for manufacturing
technologies, several multifunctional excipients have been
developed (Table 3). Some of them are good candidate for tab-
letting excipients. Due to the excellent elasticity coefﬁcient and
tensile strength, MCC is frequently used as compression of pel-
lets. Ceolus KG-801 possesses the good compressibility and
special high binding function in tablets, which is suitable for
the tablets with higher hardness, low friability and even low
content. Zeeshan et al. (2009) prepared and compacted pellets
containing pseudoephedrine hydrochloride using Celous KG-
801 granules and inert pellets as tabletting excipient. Because
tensile strength of inert pellets was inferior to coated pellets,
they were easy to crush during compression and subsequently
serve as cushioning agent that protected the coating.
3. Technological factors
In addition to composition factors, technology is of great
importance to compression of pellets likewise. The compaction
process of coated pellets can be summarized in four stages:
(i) Repositioning of pellets resulting in volume reduction of
the pellet bed.
(ii) Local surface deformation of pellets resulting in volume
reduction of the pellet bed further.
(iii) Bulk structure deformation of pellets resulting in
densiﬁcation.
(iv) Low inter- and intragranular porosity contributing to
ceased volume reduction.3.1. Coating parameters
Fluid-bed coating technology is usually used as coating of pel-
lets adopting spray gun in the bottom. Bottom spray systemnts Processing
-starch Spray-drying
rch-pregelatinized starch Spray-drying
annitol Spray-drying
a CMC Milling, spray-drying
a CMC Milling, bulk drying
a CMC Milling, spray-drying
carbonate-Starch Spray-drying
carbonate-Sorbitol Spray-drying
lloidal silicon dioxide Spray-drying
a CMC Granulation
e monohydrate-Powder cellulose Spray-drying
e monohydrate-MCC Spray drying
e monohydrate-Corn starch Spray drying
Maltodextrins Co-crystallization
l-Sorbitol Melt extrusion
l-PVA latex solids Granulation
Figure 2 Schematic diagram of bottom spray ﬂuidized bed. 1 –
Inlet ﬁlter; 2 – heater; 3 – Spray gun in the bottom; 4 – Fluidized
bed; 5 – Guide cylinder; 6 – Settling chamber; 7 – Strainer; 8 –
Bartizan; 9 – Induced draft fan.
Investigation for the quality factors on the tablets 513(known as Wurster system, Fig. 2) and air inlet are located at
the bottom of the ﬂuidized interface, which contributes to the
same direction of hydrojet and materials movement. Continu-
ous and regular movement of pellets, short distance that drop-
lets reach the surface of the particles, as well as suitable drying
efﬁciency contribute to the compact and continuous coating
ﬁlms. Technological factors affecting coating quality include
feeding capacity, supply air rate, air temperature, atomizing
pressure, spray rate, etc.
Feeding capacity usually decides ﬂuidized state of pellets.
Both too much and too little feeding capacity will reduce repro-
ducibility and coating quality. The selection of feeding capacity
must be based on the ﬂuidized bed. Suitable ﬂuidized stat can be
kept by selecting supply air rate, which reduce material loss and
enhance yield. Low supply air rate often result in the adhesion
between pellets. On the contrary, too high supply air rate will
increase friction and collision between pellets, which damages
the coating ﬁlms further. In addition, if air temperature exceeds
Tg of coating materials, volatilization rate of solvent and coat-
ing efﬁciency will be improved substantially, but too high tem-
perature will soften polymer extensively, cause adhesion
between pellets, and even affect continuity of coating process.
Atomizing pressure and spray rate decide atomization
effect of coating solution. Adhesion between pellets and
Uneven coating are dependence with too low atomizing
pressure or fast spray rate. Too high atomizing pressure not
only cracks pellets, but also causes insufﬁcient cover of coating
solution. Spray rate is decided according to the different coat-
ing solution dispersion systems. Due to the low volatility anddrying efﬁciency of aqueous dispersion, spray rate ought to
be controlled at a slower speed and conducted to heal the coat-
ing ﬁlms when necessary. Organic coating solution possesses
fast solvent evaporation and high drying efﬁciency, but safety
and residual solvents must be emphasized.
3.2. Tabletting parameters
Compression force usually affects hardness, friability and dis-
integration time of tablets. It is also related with drug release
from coated pellets. Disintegration time and hardness of tab-
lets will increase with the enhancement of compression force.
If tabletting force is too small, friability of tablets will not be
qualiﬁed. The selection of optimal compression force should
be based on the properties of pellets and composition.
3.3. Others
Mixtures often delaminate in the industrial production pro-
cess, which will not able to meet the requirements of content
uniformity. In addition to consider relevant formulation fac-
tors, Feeding ways and quantities should also be investigated.4. Conclusion
The challenges of formulating pellets into tablets are evident.
Although many problems encountered in preparation technol-
ogy restrict, to some extent, wide application of pellet-contain-
ing tablets, the dosage of tablets can be divided and persist
original characteristics of drug release after segmentation,
which provides ﬂexible medication regimen for clinical usage.
Both placid drug release in the human body and safe medica-
tion can be achieved, especially drugs with low therapeutic
index, such as metoprolol tartrate, and carbamazepine.
So far, formulating pellets into tablets is still a challenge.
Various materials and process-related parameters must be
optimized to meet quality requirements. Thereinto, pellet
cores, polymeric ﬁlms and tabletting excipients must be inves-
tigated adequately. Hardness of pellets must be high enough to
resist compression pressure. Meanwhile, good cushion elastic-
ity can avoid fragmentation of pellets. The polymer coat must
have the right combination of strength, ductility and thickness
to withstand the forces generated during compaction without
rupturing. Coating polymers that do not resist the mechanical
stresses during compaction are not suitable for the preparation
of coated pellets-containing tablets. The mechanical properties
of the polymeric ﬁlms and its response to the pressure must be
studied deliberately. For tabletting excipient, its size and den-
sity should be similar to coated pellets as far as possible to
reduce segregation. Secondly, the protection of excipient for
the pellets should be considered. Determination of ratio
between tabletting excipient and pellets must give consider-
ation to the integrity of pellets and drug content in tablets.
To achieve further development in compression technology
of coated pellets, several novel methods are adopted to opti-
mize preparation process, such as hot tabletting technique that
stress from pellets tabletting under thermal condition is much
less than general tabletting process and there are no consolida-
tion effect and elastic recovery during compression in the
meantime.
514 X. Tan, J. HuThe development of pellet tabletting is closely related with
the following aspects: The development of novel coating
polymers. The development of precision tablet devices. The
development of novel tabletting excipient. With the fast devel-
opment ofmaterial science andmechanical engineering, increas-
ing research and application will occur in the pellet tabletting,
and its industrialization can be achieved one day.References
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